Cancer clinical trials in the region Auvergne-Rhône-Alpes
509 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Brain tumors / Central nervous system tumors
#NCT03175224
#2024-514542-37-00
Required genetic anomalies
MET
Required number of previous lines of therapy
1
2
3 or more
Excluded genetic anomalies
BRAF
EGFR
NTRK-1/2/3
ALK
KRAS G12C
KRAS non G12C
RET
ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2
Endometrial cancer
#NCT05548296
#2025-524542-10-00
Required histologic sub types
Serous adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Acrivon Therapeutics
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06906341
#2024-517432-21-00
Bras A (Cancer de l'ovaire résistant au platine)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BVd (Belantamab mafodotin + Bortezomib + Dexamethasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BKd (Belantamab mafodotin + Carfilzomib + dexaméthasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BPd (Belantamab + Pomalidomide + Dexamethasone))
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Required previous treatments
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06906341
#2024-517432-21-00
Bras B (Cancer de l'ovaire sensible au platine post PARPI)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2
Lung cancer
#NCT07234058
#2024-519208-29-00
Required histologic types
Mesothelium
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
5 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2
Endometrial cancer
#NCT06906341
#2024-517432-21-00
Bras C (Cancer de l'endomètre)
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2
Lung cancer
#NCT07203053
#2025-522288-13-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
ETOP IBCSG Partners Foundation